NO20073244L - Konjugeringsprodukt - Google Patents

Konjugeringsprodukt

Info

Publication number
NO20073244L
NO20073244L NO20073244A NO20073244A NO20073244L NO 20073244 L NO20073244 L NO 20073244L NO 20073244 A NO20073244 A NO 20073244A NO 20073244 A NO20073244 A NO 20073244A NO 20073244 L NO20073244 L NO 20073244L
Authority
NO
Norway
Prior art keywords
peptide
integrin
selectively inhibits
konjugeringsprodukt
ngr motif
Prior art date
Application number
NO20073244A
Other languages
English (en)
Norwegian (no)
Inventor
Angelo Corti
Flavio Curnis
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of NO20073244L publication Critical patent/NO20073244L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20073244A 2004-12-23 2007-06-22 Konjugeringsprodukt NO20073244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63815804P 2004-12-23 2004-12-23
PCT/IB2005/004058 WO2006067633A2 (fr) 2004-12-23 2005-12-21 Produit de conjugaison

Publications (1)

Publication Number Publication Date
NO20073244L true NO20073244L (no) 2007-09-20

Family

ID=36602131

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073244A NO20073244L (no) 2004-12-23 2007-06-22 Konjugeringsprodukt

Country Status (12)

Country Link
US (2) US7795386B2 (fr)
EP (2) EP1831254B1 (fr)
JP (1) JP2008525424A (fr)
KR (1) KR20070102684A (fr)
CN (1) CN101124243A (fr)
AU (1) AU2005317684B2 (fr)
CA (1) CA2593964A1 (fr)
EA (1) EA013967B1 (fr)
ES (1) ES2388068T3 (fr)
IL (2) IL183710A (fr)
NO (1) NO20073244L (fr)
WO (1) WO2006067633A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669236B2 (en) * 2005-05-12 2014-03-11 The General Hospital Corporation Biotinylated compositions
GB0624308D0 (en) * 2006-12-05 2007-01-17 Molmed Spa Combination product
GB0708864D0 (en) * 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
EP2209805B1 (fr) 2007-10-30 2017-09-06 Philogen S.p.A. Un antigène associé à la polyarthrite rhumatoïde
ES2389474T3 (es) * 2008-05-13 2012-10-26 Molmed Spa Conjugados para el tratamiento del mesotelioma
WO2010005693A1 (fr) * 2008-06-23 2010-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés peptidiques cyclisés à motif ngr, compositions et leurs procédés d'utilisation
KR101610985B1 (ko) 2008-11-14 2016-04-08 히스토젠, 인코포레이티드 암 치료를 위한 세포외 기질 조성물
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8946379B2 (en) 2009-09-24 2015-02-03 The Regents Of The University Of California Bladder cancer specific ligand peptides
ES2872964T3 (es) * 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
WO2013148259A1 (fr) * 2012-03-28 2013-10-03 Massachusetts Institute Of Technology Signatures matricielles extracellulaires associées aux cancers et méthodes et produits associés
US10024860B2 (en) 2012-03-28 2018-07-17 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
CA2820547A1 (fr) 2012-07-02 2014-01-02 University Of South Florida (A Florida Non-Profit Corporation) Y-aapeptides rgd mimetiques et procedes d'utilisation
CA2883130A1 (fr) 2012-08-31 2014-03-06 The General Hospital Corporation Complexes de biotine pour le traitement et le diagnostic de la maladie d'alzheimer
EP2903629B1 (fr) 2012-10-03 2019-07-10 Philogen S.p.A. Conjugué d'anticorps pour utilisation dans le traitement des maladies inflammatoires de l'intestin
WO2015031084A1 (fr) 2013-08-28 2015-03-05 Jianfeng Cai Procédés de synthèse de peptides γ-aa, d'éléments constitutifs γ-aa, de banques de peptides γ-aa, et d'inhibiteurs de type peptides γ-aa d'agrégats aβ40
FR3010527A1 (fr) * 2013-09-11 2015-03-13 Univ Claude Bernard Lyon Procede de caracterisation de particules
CN103483422B (zh) * 2013-09-22 2015-06-17 中国人民解放军第四军医大学 一种ngr多肽放射性药物及其制备方法与应用
WO2015074792A1 (fr) 2013-11-25 2015-05-28 Ontochem Gmbh Procédé pour diagnostic de maladies associées à un récepteur couplé aux protéines g
RU2018105687A (ru) 2015-07-16 2019-08-16 Филоджен С.П.А. Иммуноконъюгаты на основе il22
CN108699164B (zh) * 2016-03-02 2022-06-07 法玛科技顾问股份有限公司 双重标靶药物载体
WO2020109625A1 (fr) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Traitement combiné du lymphome primaire du système nerveux central

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
WO1984002129A1 (fr) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5196511A (en) 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
AU693723B2 (en) 1995-09-11 1998-07-02 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo and methods of identifying same
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
WO1998010795A2 (fr) 1996-09-10 1998-03-19 The Burnham Institute Molecules se logeant dans une tumeur, conjugues tires de ces molecules et leurs procedes d'utilisation
AU4982200A (en) 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US7544477B2 (en) 2000-01-13 2009-06-09 Kalobios, Inc. Circularly permutated, interaction-activated proteins
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US6825167B1 (en) 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
EP1501476A2 (fr) 2000-12-11 2005-02-02 Regents of the University of Michigan Compositions et procedes de representation in situ et in vivo de cellules et de tissus
JP4029041B2 (ja) 2001-01-10 2008-01-09 アメリカ合衆国 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate

Also Published As

Publication number Publication date
EP1831254A2 (fr) 2007-09-12
AU2005317684B2 (en) 2012-02-16
KR20070102684A (ko) 2007-10-19
IL183710A (en) 2012-01-31
CA2593964A1 (fr) 2006-06-29
WO2006067633A2 (fr) 2006-06-29
WO2006067633A3 (fr) 2007-04-05
ES2388068T3 (es) 2012-10-08
US20110076234A1 (en) 2011-03-31
JP2008525424A (ja) 2008-07-17
EP1831254B1 (fr) 2012-06-06
EP2364995A1 (fr) 2011-09-14
CN101124243A (zh) 2008-02-13
IL183710A0 (en) 2008-04-13
US7795386B2 (en) 2010-09-14
EA200701053A1 (ru) 2008-06-30
US20090068106A1 (en) 2009-03-12
EA013967B1 (ru) 2010-08-30
AU2005317684A1 (en) 2006-06-29
HK1106781A1 (en) 2008-03-20
IL202570A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
EA200701053A1 (ru) Продукт конъюгации
EA200701790A1 (ru) Твёрдый фармацевтический дозированный состав
CA120928S (en) Sprayer
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CA119296S (en) Bottle
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DK1869019T3 (da) Bicycliske [3.1.0]heteroarylamider som glycintransportinhibitorer type I
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
USD529537S1 (en) Type font
ECSP088555A (es) Composiciones farmacéuticas
ATE330017T1 (de) Kallikrein gen
CA113972S (en) Track for display shelving
AU300864S (en) Trigger sprayer shroud
CA115742S (en) Sprayer tank
NL1024616A1 (nl) Depotpreparaten in de vorm van een suspensie.
CA118307S (en) Pasta dispenser disk
UY28344A1 (es) Nuevos compuestos
CA116012S (en) Product dispenser
CA119778S (en) Package
HRP20080612T3 (hr) Kombinacija tenofovira, ritonavira i tmc114
USD527411S1 (en) Type font
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
CA102731S (en) Fragrance dispenser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application